Abstract:Pleurotin is a natural compound and potent inhibitor of thioredoxin reductase (TrxR) enzyme, which is a target for cancer chemotherapy. The present study proposes a pharmacophore model for TrxR inhibitors based on the in silico analysis of 34 pleurotin analogues. The results led to ligand 33 with a flexible -SR side-chain at p-quinone and a H-bond donor -CH2NH2 at the oxepane ring. The ligand-TrxR binding free energy was -236 kJ mol-1 for 33, better than pleurotin (-166 kJ mol-1 ). The results provide a clear and practical guide to design pleurotin derivatives with anticancer potential that could expand the pharmacological potential of this class of natural products.

Pharmacophore Modeling for Pleurotin Derivatives Targeting Human Thioredoxin Reductase